Catalyst Pharma (CPRX) Stock Forecast & Price Target

Compare

2,486 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CPRX Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Catalyst

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CPRX Stock 12 Month Forecast

Average Price Target

$34.00

▲(43.95% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Catalyst Pharma in the last 3 months. The average price target is $34.00 with a high forecast of $35.00 and a low forecast of $33.00. The average price target represents a 43.95% change from the last price of $23.62.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","36":"$36","23.25":"$23.3","27.5":"$27.5","31.75":"$31.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$33.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,23.25,27.5,31.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.69,23.63692307692308,24.583846153846157,25.53076923076923,26.47769230769231,27.424615384615386,28.371538461538464,29.31846153846154,30.265384615384615,31.212307692307693,32.159230769230774,33.106153846153845,34.05307692307692,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.69,23.560000000000002,24.43,25.3,26.17,27.04,27.91,28.78,29.65,30.52,31.39,32.26,33.129999999999995,{"y":34,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,22.69,23.483076923076926,24.276153846153846,25.06923076923077,25.862307692307695,26.655384615384616,27.44846153846154,28.24153846153846,29.034615384615385,29.82769230769231,30.62076923076923,31.413846153846155,32.206923076923076,{"y":33,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.89,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.53,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.87,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.56,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.9,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.91,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.27,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.69,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$34.00

Lowest Price Target$33.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

$35

Buy

48.18%

Upside

Reiterated

11/10/25

Catalyst Pharma's Strategic Growth and Market Positioning: A Promising Outlook

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)

Leland Gershell

Oppenheimer

$32→$33

Buy

39.71%

Upside

Reiterated

11/07/25

Catalyst Pharmaceuticals price target raised to $33 from $32 at OppenheimerCatalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

Jason Gerberry

Bank of America Securities

$34→$35

Buy

48.18%

Upside

Reiterated

11/06/25

Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)

Samantha Semenkow

Citi

$31→$33

Buy

39.71%

Upside

Reiterated

11/06/25

Catalyst Pharmaceuticals price target raised to $33 from $31 at CitiCatalyst Pharmaceuticals price target raised to $33 from $31 at Citi

Joel Beatty

Robert W. Baird

$28→$32

Buy

35.48%

Upside

Reiterated

03/03/25

Catalyst Pharmaceuticals price target raised to $32 from $28 at BairdCatalyst Pharmaceuticals price target raised to $32 from $28 at Baird

Sudan Loganathan

Stephens

$33→$40

Buy

69.35%

Upside

Reiterated

02/28/25

Catalyst Pharmaceuticals price target raised to $40 from $33 at StephensCatalyst Pharmaceuticals price target raised to $40 from $33 at Stephens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

$35

Buy

48.18%

Upside

Reiterated

11/10/25

Catalyst Pharma's Strategic Growth and Market Positioning: A Promising Outlook

Joon Lee

Truist Financial

―

Buy

―

Reiterated

11/10/25

Analysts Offer Insights on Healthcare Companies: Catalyst Pharma (NASDAQ: CPRX), Rapid Micro Biosystems (NASDAQ: RPID) and Nurix Therapeutics (NASDAQ: NRIX)

Leland Gershell

Oppenheimer

$32→$33

Buy

39.71%

Upside

Reiterated

11/07/25

Catalyst Pharmaceuticals price target raised to $33 from $32 at OppenheimerCatalyst Pharmaceuticals price target raised to $33 from $32 at Oppenheimer

Jason Gerberry

Bank of America Securities

$34→$35

Buy

48.18%

Upside

Reiterated

11/06/25

Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)

Samantha Semenkow

Citi

$31→$33

Buy

39.71%

Upside

Reiterated

11/06/25

Catalyst Pharmaceuticals price target raised to $33 from $31 at CitiCatalyst Pharmaceuticals price target raised to $33 from $31 at Citi

Joel Beatty

Robert W. Baird

$28→$32

Buy

35.48%

Upside

Reiterated

03/03/25

Catalyst Pharmaceuticals price target raised to $32 from $28 at BairdCatalyst Pharmaceuticals price target raised to $32 from $28 at Baird

Sudan Loganathan

Stephens

$33→$40

Buy

69.35%

Upside

Reiterated

02/28/25

Catalyst Pharmaceuticals price target raised to $40 from $33 at StephensCatalyst Pharmaceuticals price target raised to $40 from $33 at Stephens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Catalyst Pharma

1 Month

xxx

Success Rate

9/13 ratings generated profit

Average Return

+5.69%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 69.23% of your transactions generating a profit, with an average return of +5.69% per trade.

3 Months

xxx

Success Rate

9/13 ratings generated profit

Average Return

+7.09%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +7.09% per trade.

1 Year

Joon LeeTruist Financial

Success Rate

24/28 ratings generated profit

Average Return

+40.88%

reiterated a buy rating last month

Copying Joon Lee's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +40.88% per trade.

2 Years

xxx

Success Rate

27/28 ratings generated profit

Average Return

+68.93%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 96.43% of your transactions generating a profit, with an average return of +68.93% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CPRX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CPRX has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CPRX average Analyst price target in the past 3 months is 34.00.

Each month's total comprises the sum of three months' worth of ratings.

CPRX Financial Forecast

CPRX Earnings Forecast

Next quarter’s earnings estimate for CPRX is $0.31 with a range of $0.21 to $0.35. The previous quarter’s EPS was $0.42. CPRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year CPRX has Performed in-line its overall industry.

CPRX Sales Forecast

Next quarter’s sales forecast for CPRX is $141.49M with a range of $136.14M to $149.64M. The previous quarter’s sales results were $148.39M. CPRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year CPRX has Performed in-line its overall industry.

CPRX Stock Forecast FAQ

What is CPRX’s average 12-month price target, according to analysts?

Based on analyst ratings, Catalyst Pharmaceutical Partners’s 12-month average price target is 34.00.

What is CPRX’s upside potential, based on the analysts’ average price target?

Catalyst Pharmaceutical Partners has 43.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is CPRX a Buy, Sell or Hold?

Catalyst Pharmaceutical Partners has a consensus rating of Strong Buy which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Catalyst Pharmaceutical Partners’s price target?

The average price target for Catalyst Pharmaceutical Partners is 34.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $33.00. The average price target represents 43.95% Increase from the current price of $23.62.

What do analysts say about Catalyst Pharmaceutical Partners?

Catalyst Pharmaceutical Partners’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of CPRX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Catalyst Pharma (CPRX) Stock Forecast & Price Target

CPRX Analyst Ratings

CPRX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Catalyst Pharma

CPRX Analyst Recommendation Trends

CPRX Financial Forecast

CPRX Earnings Forecast

CPRX Sales Forecast

CPRX Stock Forecast FAQ

Detailed List of Analyst Forecasts